EUVIMEDEUVIMED entdecken
Open Access

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

Robert A Smith iD, Dana N Raugi, Robert S Nixon, Moussa Seydi, Nicolas A Margot, Christian Callebaut, Geoffrey S Gottlieb iD, University of Washington–Senegal HIV-2 Study Group

The Journal of Infectious Diseases · 15.05.2024 · 229 (5) · 1290-1294

DOI: 10.1093/infdis/jiad562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 07.12.2023. Verfasst von Robert A Smith und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle. Hauptthemen laut MEDLINE: HIV-2, Drug Resistance, Viral. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti–HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-2Drug Resistance, ViralHumansCell LineMutationHIV InfectionsHIV-1Anti-HIV Agents

Stichwörter der Autor:innen

HIV-1HIV-2SIVantiretroviral therapylenacapavir

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle.
  • Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle.
  • Service des Maladies Infectieuses et Tropicales, Centre Hospitalier National Universitaire de Fann, Dakar, Senegal.
  • Clinical Virology, Gilead Sciences Inc, Foster City, California.
  • Department of Global Health, University of Washington, Seattle.

ORCID-Profile: Robert A Smith, Geoffrey S Gottlieb

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • (NIAID)
  • NIH HHS
  • University of Washington Center for AIDS Research
  • Stanford HIV Drug Resistance Database Program
  • National Institutes of Health

Zitieren

APA

Smith, R. A., Raugi, D. N., Nixon, R. S., Seydi, M., Margot, N. A., Callebaut, C., Gottlieb, G. S., & University of Washington–Senegal HIV-2 Study Group (2024). Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. The Journal of Infectious Diseases, 229(5), 1290-1294. https://doi.org/10.1093/infdis/jiad562

Vancouver

Smith RA, Raugi DN, Nixon RS, Seydi M, Margot NA, Callebaut C, et al. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants. The Journal of Infectious Diseases. 2024;229(5):1290-1294. doi:10.1093/infdis/jiad562

BibTeX
@article{Smith2024,
  author = {Smith, Robert A and Raugi, Dana N and Nixon, Robert S and Seydi, Moussa and Margot, Nicolas A and Callebaut, Christian and Gottlieb, Geoffrey S and University of Washington–Senegal HIV-2 Study Group, University of Washington–Senegal HIV-2 Study Group},
  title = {Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {229},
  number = {5},
  pages = {1290--1294},
  doi = {10.1093/infdis/jiad562}
}
Kostenlos starten →